LOS ANGELES CAPITAL MANAGEMENT LLC
Position in LXEO — Lexeo Therapeutics, Inc.
CIK 1177206
LOS ANGELES, CA
Position in LXEO
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$212,787
+$98,046 QoQ
Shares Held
37,071
+220.8% QoQ
Ownership
0.047%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 36%
Shared 0%
None 64%
Common Shares in LXEO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $690,033,476 across 153 Biotechnology names. LXEO ranks #75 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
2,144,847 | $201,872,999 | |
| 2 | EXEL |
Exelixis, Inc.
|
3,102,634 | $133,071,972 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
78,880 | $60,945,843 | |
| 4 | RPRX |
Royalty Pharma plc
|
971,927 | $46,623,338 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
689,915 | $44,589,206 | |
| 6 | CAI |
Caris Life Sciences, Inc.
|
2,289,602 | $40,938,083 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
88,278 | $29,208,541 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
64,937 | $28,996,967 |
All Filings in LXEO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $212,787 | 37,071 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $114,741 | 11,555 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $73,538 | 11,075 | Shares | Sole | 2025-10-20 | |
| No filing history on record for this holder in this stock. | ||||||